Edwards Lifesciences Accrued and other liabilities (Note 2) decreased by 22.9% to $1.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.6%, from $1.20B to $1.20B. Over 5 years (FY 2020 to FY 2025), Accrued and other liabilities (Note 2) shows an upward trend with a 18.4% CAGR.
An increase suggests rising operational costs or timing differences in payments, while a decrease indicates the clearing of these obligations.
This line item includes various short-term obligations that have been incurred but not yet invoiced or paid, such as emp...
Common across all companies; reflects the scale of operational activity.
current_liabilities_accrued_and_other_liabilities_current| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $802.80M | $802.30M | $767.20M | $783.30M | $739.50M | $795.00M | $876.10M | $939.90M | $1.02B | $969.10M | $873.70M | $902.40M | $1.75B | $1.28B | $1.20B | $1.21B | $1.39B | $1.56B | $1.20B |
| QoQ Change | — | -0.1% | -4.4% | +2.1% | -5.6% | +7.5% | +10.2% | +7.3% | +8.9% | -5.4% | -9.8% | +3.3% | +93.4% | -26.5% | -6.7% | +1.5% | +14.8% | +12.0% | -22.9% |
| YoY Change | — | — | — | — | -7.9% | -0.9% | +14.2% | +20.0% | +38.5% | +21.9% | -0.3% | -4.0% | +70.4% | +32.3% | +36.9% | +34.6% | -20.1% | +21.8% | +0.6% |